Medicines Discovery Catapult and Astral Systems secure £1.54m to develop the UK’s radiopharmaceutical lab of the future
Medicines Discovery Catapult (MDC) and Astral Systems have been awarded £1.54 million from Innovate UK to develop digital and automated laboratory processes that will support the production of next-generation radiopharmaceuticals, helping the UK meet growing demand for these precision medicines.
Radiopharmaceuticals can be used for both diagnosis and treatment, and they have the potential to drive game-changing breakthroughs for cancer patients. More than 700,000 NHS procedures rely on these medicines each year, and demand is set to increase as the next generation of radiopharmaceutical therapies moves through development to the clinic.
Because radiopharmaceuticals contain a radioactive element (a radionuclide), they pose manufacturing challenges unlike those of most other medicines. The active material decays over time, so medicines must be made and delivered to patients quickly to ensure maximum potency. Any delay in production can compromise the effectiveness of the medicine and could cost lives.
The laboratory steps involved in radiopharmaceutical production are often managed separately, relying on disconnected systems, manual record-keeping and handovers between stages. When working with rapidly decaying materials, speed and accuracy are vital. Manual, disconnected systems increase the risk of errors and reduce the efficiency and reliability of development. As demand for radiopharmaceuticals grows, modernising these processes will be essential to support future scale-up.
Combining MDC’s expertise in radiopharmaceutical development with Astral Systems’ compact multi-state fusion devices and engineering capabilities, the partners will create the digital infrastructure needed for the radiopharmaceutical lab of the future. They will bring fragmented radiopharmaceutical laboratory processes into a single, integrated and automated workflow that enables efficient data recording and transfer between steps.
The workflow will also incorporate virtual ‘digital avatars’: computer models that let scientists test and optimise processes virtually before committing laboratory time, supporting better decision-making and accelerating development.
Using Copper-64 and Copper-67 as pilot radionuclides, an emerging pair for both diagnostic imaging and targeted radiopharmaceutical therapy, the project will develop and demonstrate approaches that can be adapted to other radionuclides and transferred across laboratories.
By creating a connected and data-driven framework for radiopharmaceutical development, the project will help make production more efficient, reproducible and scalable. This will strengthen the UK's capability to translate promising radiopharmaceutical research into clinically available medicines, accelerating patient access to these innovative treatments.
Dr Mike Strange, CEO, Medicines Discovery Catapult, said:
The UK has world-class science in radiopharmaceuticals, but it needs the development and manufacturing capability to match if we are to realise the economic and health benefits of this fast-growing field. This project is an important step towards ensuring the digital infrastructure is in place to support the next generation of radiopharmaceutical development in the UK and help bring new treatments closer to patients.
Talmon Firestone, CEO, Astral Systems, added:
Isotopes decay constantly, so every step between the lab and the patient matters. This project brings those steps together into one automated, digital workflow, giving researchers more reliable data and the UK a firmer base for the treatments that follow.
Dr Hareklea Markides, Innovation Lead – Medicines Manufacturing at Innovate UK, said:
This project demonstrates the UK’s strength in medicines manufacturing innovation and highlights the value of our investment through the Labs of the Future programme. By supporting ambitious UK businesses to develop next-generation medicines and manufacturing technologies, we are helping to drive growth, productivity and competitiveness in line with both Innovate UK’s strategy and the UK Industrial Strategy. With demand for radiopharmaceuticals continuing to grow, a digital-first production process has the potential to improve resilience, increase access and ultimately benefit patients.
The project is funded by Innovate UK through the Labs of the Future competition, part of the Transforming Medicines Manufacturing Innovation programme.